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Abstract 
 
The main goal of this research project was the detection and semi-quantitation of the parent 
drugs promethazine (PMZ), and chlorpromazine(CPZ) along with selected metabolites 
promethazine sulfoxide (PMZSO), desmethylpromethazine (DPMZ), chlorpromazine sulfoxide 
(CPZSO), and desmethylchlorpromazine (DCPZ) in the skeletal remains of rats. We sought to 
evaluate the relative distribution of structural analogues (promethazine (PMZ) and 
chlorpromazine (CPZ)), and the relationship of multiple metabolites to the parent drug.  The first 
phase of the project was to consist of method development and validation and the second phase 
would be examining a large number of rat bone samples exposed to different drug exposure 
patterns. For the analytical method, drug extraction is completed using microwave assisted 
extraction (MAE), followed by sample clean-up by microplate solid-phase extraction (MPSPE) 
and instrumental analysis by ultra-high performance liquid chromatography coupled to 
photodiode array detection (UHPLC-PDA).  During method development and validation, 
extraneous compounds appeared in the chromatograms. The production of unknown compounds 
hindered the ability to meet the validation criteria. Thus, the new objective of the research was 
characterization of the unknown compounds by ultra-high performance liquid chromatography 
coupled to quadrupole time-of-flight mass spectrometry (UPLC-qTOF-MS), comparing the 
extent of degradation for different extraction conditions, and validation of a new method that 
does not promote degradation.  
 
Keywords: Forensic toxicology, Promethazine, Chlorpromazine, Oxidation, UHPLC-PDA, 
UHPLC-QTOF-MS 
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Chapter 1 
 
1.1 Forensic Toxicology 
Forensic toxicology is the application of toxicology where the adverse effects of drugs and 
chemicals on the human body have legal repercussions (1). Forensic toxicologists work with 
pathologists, coroners, and police officers to help establish the role of alcohol, drugs, or poisons 
in the cause of death, or in the contribution of the crime. It is a multidisciplinary field with four 
main disciplines: postmortem forensic toxicology, human performance toxicology, and 
workplace drug testing (1,2). Therefore, toxicological investigations commonly involve 
confirming a lethal dose of drugs as the cause of death, incidents of driving under the influence, 
and detecting the use of drugs in the workplace. It includes testing for both therapeutic drugs and 
drugs of abuse (1). The most commonly analyzed biological specimen is blood because you can 
relate drug concentrations to pharmacological effects and databases of drug levels in blood exist 
to assist with interpretation (1). Depending on the nature of the case and specimens available, 
other biological samples may be analyzed such as vitreous humour, urine, liver, stomach 
contents, hair or saliva.  Toxicological analysis of bone is not very common because 
interpretation of drug concentrations is complicated given that a reference database does not 
exist, and there is a lack of published research and casework containing bone as the biological 
sample. However, in cases of extreme decomposition, bone may be considered for analysis 
because the conventional specimens such as blood, urine, or other tissues are not present. The 
sample analysis in a toxicological examination consists of four main steps: detection of any 
drugs or chemicals using a screening method, identification of any parent drugs, metabolites or 
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chemicals using a confirmatory method, quantification of the analytes that were identified and 
lastly interpretation of the analytical results (2). 
1.2 Phenothiazines: Chlorpromazine and Promethazine 
Promethazine and chlorpromazine belong to the drug classification known as phenothiazine 
derivatives due to their structure. The chemical structure of phenothiazines consists of a tricyclic 
structure in which two benzene rings are joined by a sulfur and a nitrogen atom. The nature and 
position of the substituents determines the pharmacological activity. The chlorine substituent at 
position 2 for chlorpromazine is said to increase the antipsychotic efficacy (3). The aliphatic side 
chain at position 10 is also responsible for differing pharmacological properties between 
promethazine and chlorpromazine (3). Promethazine only has two carbon atoms separating the 
amino group from position 10 whereas chlorpromazine has three carbon atoms.  
 
 
Figure 1:General phenothiazine structure (A), Promethazine (B), and Chlorpromazine (C). 
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1.2.1 Chlorpromazine 
Chlorpromazine(CPZ) is marketed under the trade names Thorazine and Largactil and is an older 
antipsychotic drug. It was first available as a prescription drug in 1953 and is prescribed for the 
treatment of psychotic disorders, mainly schizophrenia (4). It is distributed in the form of tablets 
and a syrup for oral administration in a hydrochloride salt composition (4). A single dose of 
chlorpromazine for adults is typically 25-100mg (4). Although knowledge of the exact actions 
underlying antipsychotic drugs remains incomplete and is drug-specific, studies have shown that 
the principal mechanism of action of antipsychotics is the affinity of these drugs to bind to 
dopamine D2 receptors (3,5). By binding to the dopamine D2 receptors they block the dopamine 
receptors by acting as receptor antagonists. This reduces dopamine levels in the brain which are 
abnormally elevated in a psychotic state (5).  CPZ is absorbed readily from the gastrointestinal 
tract after oral administration but undergoes considerable first-pass metabolism in the liver (1). 
Thus, depending on the extent of first-pass metabolism, its bioavailability and effectiveness 
varies. CPZ has a large volume of distribution of 20 L/kg which demonstrates it is extensively 
distributed throughout the body (1). It is highly bound to plasma proteins which results in 
localization in tissues with vast blood supply such as the brain, lungs, and liver (1). It can also 
cross the blood-brain barrier and transfer across the placental barrier (3,6).  CPZ is primarily 
metabolized in the liver by cytochrome P450 to form mostly polar metabolites which are 
excreted in the urine (3,6). Biotransformation of chlorpromazine commonly occurs by 
sulfoxidation, demethylation, hydroxylation and glucuronidation (3,6).  Therefore, it is 
metabolized to a great extent, with at least 12 different metabolites identified (1).  However, the 
predominant metabolites are the sulfoxide, demethylated, and hydroxy products. The elimination 
phase of chlorpromazine is slow and is characterized by a half-life of 18-30 hours (3,6). As with 
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most prescribed drugs, side effects can occur with chlorpromazine depending on the dose 
consumed. There may be some initial drowsiness, slowness in response, confusion, and blurred 
vision however; some tolerance to the adverse effects usually develops after a few days (3).  At 
high dose levels, more serious side effects can develop such as orthostatic hypotension, acute 
dystonia, akathisia, parkinsonism, and neuroleptic malignant syndrome (3). Unfortunately, the 
photochemical properties of CPZ can also induce undesirable side effects (7-11). The interaction 
of light with CPZ present in the skin and eyes often results in photosensitization (7-11). This 
may take the form of phototoxic or photoallergic side effects which include exaggerated 
sunburns, hyperpigmentation of the skin, and ocular opacity (7-11). Therefore, individuals who 
are taking CPZ should refrain from exposure to sunlight and artificial light.  Based on laboratory 
studies, single oral doses of chlorpromazine as low as 25 mg given to normal healthy adult 
volunteers can negatively impact psychomotor performance (4). CPZ can also influence the 
actions of other drugs, most notably other CNS depressants (3). It can prolong or intensify the 
effect of sedatives, analgesics, alcohol, and cold remedies. A therapeutic range for serum drug 
concentrations of chlorpromazine has been established to be 50-500 ng/ml with concentrations 
greater than 750 ng/ml considered toxic (1). However, serum concentrations ranging from 800 to 
1,500 ng/ml have been observed in patients that survived (6). This significant overlap that can 
exist between therapeutic and toxic drug concentration is due to tolerance and inter-individual 
variation and is a problem in the interpretation of chlorpromazine drug concentrations.  Another 
factor that confounds interpretation is the fact that blood levels do not correlate well with clinical 
effects because many metabolites of chlorpromazine are active and may contribute to biological 
activity (3,6). Although new generation antipsychotics are replacing conventional older ones 
such as chlorpromazine, new experimental uses of CPZ have been proposed for the treatment of 
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anorexia nervosa (12), and anti-migraine therapies (13,14). Currently, reports of fatalities from 
CPZ overdose are rare because it not prescribed as frequently, but it is possible it will be detected 
in overdoses with ingestion of other drugs. The analytical methods which have been developed 
to detect and identify CPZ in biological samples are shown in Table 1.  
 
 
 
Figure 2:Chlorpromazine and metabolites: desmethylchlorpromazine (DCPZ) and 
chlorpromazine sulfoxide (CPZSO) 
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Figure 3:Promethazine and metabolites: desmethylpromethazine (DPMZ) and promethazine 
sulfoxide (PMZSO) 
 
1.2.2 Promethazine 
Promethazine(PMZ) is available as an over-the-counter drug known as Phenergan. It is an 
antihistamine used to treat allergic or anaphylactic reactions, motion sickness, nausea, and 
vertigo (4). It also exhibits sedative effects and therefore can be found as an ingredient in 
sleeping pills.  Similar to CPZ, PMZ is supplied as a hydrochloride salt in tablets or syrup for 
oral administration (4). Other routes of administration include rectal, intravenous and 
intramuscular (5). However, complications appear most often when administering PMZ 
intravenously (15,16). It is a frequently used drug in emergency departments to treat headaches 
and nausea but needs to be given slowly because it is highly corrosive to blood vessels and 
surrounding tissue (15,16).  There have been cases of promethazine related-tissue toxicity, some 
requiring amputation (15,16). The mechanism of action of PMZ is poorly understood, however it 
is known that it is an H1 antagonist. The structure of PMZ is comparable enough to histamine 
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that is penetrates the blood-brain barrier and binds to central H1 receptors, blocking the actions 
of histamine on these receptors (5). Following oral administration, PMZ is well absorbed and 
peak concentrations are achieved within two hours with effects that usually last four to six hours 
(3). The major site of metabolism is the liver by the cytochrome P450 enzyme system and most 
of the metabolites are excreted in the urine (1,3). Both N-demethylation and sulfoxidation 
biotransformation are common, producing the predominant metabolites which are promethazine 
sulfoxide and desmethylpromethazine (1,3). The elimination half-life of PMZ is approximately 
9-16 hours (3). Consumption of PMZ may be associated with side effects, though the incidence 
and severity of side effects will vary between individuals. The most common side effect is 
sedation, others include drowsiness, blurred vision, tinnitus, and disorientation (3,5).  Like 
chlorpromazine, Promethazine is known to cause both phototoxic and photoallergic side effects 
in individuals due to its photochemical properties (7-11). Individuals taking PMZ should be 
warned not to drive or drink alcohol because of its sedation potential; simultaneous ingestion 
with other CNS depressants will produce additive effects that impair motor skills (3,4). 
Laboratory studies have demonstrated that a single oral dose of promethazine given to healthy 
volunteers can impair task performance and cause sedation for up to 12 hours (4). Although, 
antihistamines are deemed relatively safe, cases of promethazine poisoning have been reported. 
In instances where poisoning occurred the dose ingested ranged from 350 mg-1250 mg, where a 
daily oral dose in adults ranges from 25 mg to 150 mg (4,18). According to Parker S.D et al. 
(18), it is possible the abuse and dependence of promethazine is under-recognized and needs to 
be more acknowledged (19).  Promethazine has been encountered in post-mortem examinations 
of multiple drug toxicity and more recently is being found in combination with codeine in a 
mixture referred to as “purple drank” (20). Hence, it is a possibility PMZ will be encountered in 
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forensic toxicological analysis. Presently, PMZ and some of its metabolites in biological samples 
have been analyzed by multiple methods. These are listed in Table 1.  
Table 1: Analytical Methods Used to Identify Promethazine and Chlorpromazine in Biological 
Samples 
Analyte Sample 
Matrix 
Sample 
Preparation 
Analytical 
Method 
Limit of 
Detection 
(ng/ml) 
Reference 
PMZ Plasma Pipette Tip 
SPE C18 
GC-MS 20n Hasegawa et 
al., 2006 (20) 
PMZ and 
metabolites 
Urine Online solid-
phase 
extraction and 
column 
switching 
HPLC-UV PMZ:3.7 
PMZSO:2.5 
DPMZSO:2.5 
DPMZ:2.5 
Song, Q., and 
Putcha, L., 
2001 (21) 
PMZ Blood Hollow-fiber 
drop-to-drop 
solvent 
microextraction 
GC-MS 18 Tapadia, K., et 
al., 2011 (22) 
PMZ Urine 
and 
plasma 
Liquid-liquid 
extraction 
LC-MS 1.0 Campanero, 
M. A., et al., 
1998 (23) 
PMZ and 
metabolites 
Plasma Liquid-Liquid 
Extraction 
HPLC-UV PMZ:1.0 
PMZSO:2.0 
DPMZSO:1.5 
DPMZ: 1.5 
Vanapalli, S. 
R., et al. ,2001 
(24) 
PMZ Serum Liquid-Liquid 
Extraction 
HPLC-UV 1.0 Wallace, J. E., 
et al., 1981 
(25) 
CPZ Urine Liquid-Liquid 
Extraction 
CE-ECL 1.5 Li, et al., 2006 
(26) 
CPZ Blood Solid-Phase 
Extraction 
GC-NPD 46 de la Torre, C. 
S.,et al.,2005 
(27) 
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CPZ Urine 
and 
serum 
Hollow fiber 
liquid phase 
microextraction 
HPLC-UV 0.5 Sobhi, H. R., 
et al. 2007 
(28) 
CPZ Plasma Solid-phase 
extraction 
HPLC-
Coulometric 
Detection 
0.17 Saracino, M. 
A.,et al. 2008 
(29) 
CPZ Serum Stir-bar 
sorptive 
extraction 
HPLC-UV 0.7 Bazhdanzadeh, 
S., et al. ,2011 
(30) 
CPZ Urine Molecularly 
imprinted 
solid-phase 
extraction 
HPLC-UV 80 Song, S., et 
al.,2008 (31) 
PMZ and 
CPZ 
Plasma Dilution HPLC-UV 100 Pistos, C., 
Stewart, J. T., 
2003 (32) 
PMZ and 
CPZ 
Urine Hollow-fiber 
liquid phase 
microextraction 
GC-FID PMZ:1.4 
CPZ:9.9 
Xiao, Q., Hu, 
B, 2010(33) 
PMZ and 
CPZ 
Plasma Micropipette 
tip solid-phase 
extraction 
GC-MS PMZ: 6 
CPZ: 2 
Kumazawa, 
T., et al. 2011 
(34) 
PMZ and 
CPZ 
Urine Dynamic 
liquid-phase 
microextraction 
HPLC-UV PMZ:48 
CPZ:31 
Cruz-Vera, 
M., et al.,2009 
(35) 
 
1.3 Stability of Phenothiazines 
 
In forensic toxicology, knowledge of the stability of drugs in biological samples during storage, 
handling and analysis is important for the interpretation of findings.  Drug concentrations can 
change from the time of death to the sample acquisition. This may lead to a discrepancy between 
the initial concentration and the concentration result from the toxicological analysis, which can 
result in unreliable interpretations. In reference to the literature, stability is defined as the 
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“influence of time on the concentration of the analyte in a given matrix under specific 
conditions” (36,37).  Evaluation of the stability of drugs is often completed as part of the method 
development and validation, but unless the stability experiments are stated in the title, 
information about a particular drug is very difficult to retrieve. This is the case for promethazine 
and chlorpromazine; information concerning long-term stability or stability in a variety of 
matrices under different conditions is hard to locate.  The different types of stability experiments 
that should be performed include: long-term stability in the sample matrix, freeze/thaw stability, 
stability of the analyte during sample preparation, and stability of the analyte in extracts under 
conditions of analysis (36,37).  The literature publications regarding the stability of 
chlorpromazine and promethazine mainly involve the effect of sample storage at different 
temperatures. None of the articles describe promethazine as unstable during storage, yet 
chlorpromazine is described as having stability issues. The stability results for CPZ are 
contradictory; one article mentioned CPZ showed losses when stored at -20
0
C in blood after 20 
weeks (36), on the other hand, another study found CPZ to be stable in blood over 84 days when 
stored at -20
0
C (38). Other articles investigated the stability of CPZ in serum and plasma where 
the results indicated it was stable, however one study did report an increase in CPZ concentration 
in a patients’ blood serum sample stored below 00C due to reconversion of the metabolite to the 
parent drug (37).  
 
1.3.1 Oxidation of Chlorpromazine and Promethazine 
 
The phenothiazines exhibit many chemical properties which may account for their instability or 
reactivity. Their most well-known property is their susceptibility to oxidation by a number of 
different oxidizing agents, ex.,K2Cr2O7, NH4VO3, Ce(SO4)2, KBrO3, KIO3, KIO4,NaNO2, H2O2 
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or by exposure to light (39,40). This property enables their application as redox indicators and 
use in catalytic methods (39). They also react with some metals and organic substances to form 
ion-association complexes (39). The general reaction mechanism for the oxidation of 
phenothiazines describes the first step as reversible and is the loss of an electron to produce a 
coloured radical cation (Fig 4, 39, 40-42) In the second step the free radical is oxidized further to 
generate a colourless sulfoxide (Fig 4,40-42). The susceptibility of phenothiazines to oxidation 
and the type of oxidation products that form depend on the following factors: acidity of the 
solution, concentration of reagents, temperature and substituents at position 2 and 10 on the ring 
(40-42). Therefore, although the sulfoxide commonly forms, depending on the reaction 
conditions the nitrogen atoms may also be oxidized to form the N-oxide (43). Other oxidation 
products result from cleavage of the lateral side chain and electrophilic substitutions (44). 
Literature studies have demonstrated that chlorpromazine and promethazine are easily oxidized 
(45-49).  They will degrade in the presence of acid or base and degradation is increased if 
external factors such as light or temperature are involved (45-49). Furthermore, promethazine 
sulfoxide and chlorpromazine sulfoxide are the most commonly identified degradation products 
(45-49). According to the toxicology literature, depending on the extraction conditions CPZ 
metabolites in plasma samples were converted back into CPZ (50). The reduction of CPZNO to 
CPZ leads to deceptively high levels of CPZ (51).  The same authors observed the oxidation of 
CPZ to CPZSO in whole blood due to the set-up of the analytical procedure (51,52). They also 
noted that whole blood presents a challenge compared to plasma because the hemoglobin 
catalyzes the sulfoxidation (51,52).  In summary, the oxidation of phenothiazines by chemical, 
photochemical, electrochemical, and enzymatic methods has been extensively studied, however 
it is a complex subject that is very dependent on the experimental conditions. Thus, the 
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mechanisms and products formed vary considerably. Also, there are very few articles that 
highlight the measures that should be taken to avoid degradation. Even more concerning is the 
rare mention of the problem of instability of the phenothiazines in the toxicology literature.  
 
Figure 4: Mechanism of oxidation for phenothiazine derivatives 
 
 1.4 Sample Preparation 
In most cases, prior to separation and detection by analytical instrumentation the sample will 
require some form of treatment and preparation. The sample preparation can be the most time-
consuming, tedious and expensive step of the analytical procedure.  Furthermore, it has an 
influence on the selectivity, sensitivity, accuracy and precision of the results obtained. Therefore, 
optimization of the sample preparation procedure is very important.  Although, sample 
preparation can be employed using a wide range of techniques, all methods share the same 
primary goal: to remove as many interfering compounds as possible. Many factors are taken into 
consideration when choosing a particular sample preparation procedure, such as the nature of the 
sample matrix, the properties of the target analyte, the limit of detection required and the type of 
separation and detection utilized. The different types of sample preparation methods generally 
include: dilution, precipitation, centrifugation, filtration, and extraction. Solid-phase extraction 
and filtration are the two sample preparation methods discussed below based on their inclusion in 
this research project.  
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1.4.1 Solid-Phase Extraction 
For many years, liquid-liquid extraction (LLE) was the most common and widespread sample 
preparation method, however currently, solid-phase extraction (SPE) is gaining popularity at the 
expense of LLE procedures.  The principle of SPE is similar to that of LLE, which involves the 
partitioning of the analyte between two phases, in LLE it is two immiscible liquid phases (53). In 
SPE, the analytes to be extracted are distributed between a solid phase (sorbent) and a liquid 
(sample matrix) (53,54). The separation is based on the analytes having a greater affinity for the 
solid phase than the sample matrix (53,54).  The advantages of SPE over LLE which have 
contributed to its growth and widespread use include: decreased solvent consumption, versatility 
(as many sorbent formats and protocols are available), ease of automation, increased extraction 
efficiency (stronger retention and selectivity available), and reduction in time and labour 
(simultaneous analysis of multiple samples) (53-55). There are various types of SPE sorbent 
formats available 
 such as cartridges, disks, syringes, pipette tip, and 96-well plate (55,56). The 96-well plate 
configuration is a newer format that has become common because you can process 96 individual 
samples simultaneously in parallel (55,56). The principle SPE objectives consist of 1. Removal 
of interferences: to identify and quantitate the analyte of interest, and reduce ion suppression or 
enhancement 2. Increase the concentration of the analyte: to achieve low limits of detection 
depending on the application 3. Ability to fractionate the sample matrix: to separate different 
classes of compounds. (53,54).  
 
Compounds are retained by the SPE sorbent based on the mechanism of interaction between the 
sorbent and the analyte (53,54). The different mechanisms of retention are based on van der 
14 
 
Waals forces, hydrogen bonding, dipole-dipole interactions, pi-pi interactions, hydrophobic 
interactions, hydrophilic interactions and electrostatic interactions (53,54).  In reversed phase 
SPE, the separation involves a non-polar stationary phase and a polar matrix, with the analyte 
being mostly non-polar (53,54).  In normal phase SPE, the analyte has polar functional groups to 
interact with the polar stationary phase and the sample matrix is non-polar (54,57). For ion-
exchange SPE, the compounds must be charged in solution which is achieved by manipulating 
the pH (54,57). The analyte and the sorbent must be oppositely charged for retention to occur. A 
cation exchange stationary phase is used to retain positively charged compounds and an anion 
exchange stationary phase is used to retain negatively charged compounds (54,57).  If a mixed-
mode sorbent is utilized, then two modes of retention are included in the stationary phase 
(54,55). For example, the sorbent can incorporate reversed-phase and ion-exchange to enable 
greater retention and selectivity (54,55).  In forensic toxicology mixed-mode sorbents are 
commonly employed because many drugs contain aromatic and alkyl functionalities with a 
nitrogen that can be readily protonated, allowing them to participate in hydrophobic, aromatic, 
and electrostatic interactions and separate from acidic compounds.  
 
The experimental procedure for SPE consists of five major steps: conditioning, equilibration, 
loading, washing, and elution (53,54). Each step requires optimization because the solvent 
selection is important and depends on the analyte and stationary phase. For the first step, a strong 
organic solvent conditions the sorbent by activating the stationary phase so the compounds can 
properly interact with the sorbent pores (53,54).  The purpose of the equilibration step is to 
replace the organic solvent by a liquid that is similar to the composition of the sample matrix 
(53,54). Next, the sample which contains the analytes of interest is applied to the cartridge or 
15 
 
well and allowed to flow by gravity (53,54).  The wash step provides for the removal of 
interferences while retaining the analyte (53,54). A vacuum manifold can be utilized to dry the 
sorbent if changing between aqueous and organic solvents and to control the flow rate (53,54). 
The last step is the elution of the analyte from the sorbent with a solvent that has the required 
eluent strength, with the goal of recovering as much of the analyte as possible (53,54).  Finally, a 
dry down and reconstitution step is often required to evaporate the strong elution solvent and add 
mobile phase to ensure the sample is compatible with the chromatography system (54).  
SPE can be used for numerous applications and as a result there are many publications 
describing SPE methods (55,56). It is an active area of research with recent developments 
focused on new formats, new selective sorbents, and automation (55,56).  
1.4.2 Filtration 
Filtration is an easy and straightforward method of sample preparation. Most filtration methods 
consist of a porous membrane that involves a size-exclusion mechanism which allows small 
molecules to pass through freely but stops the passage of larger molecules (58). Its purpose is to 
remove particles from solutions or dissolved substances. It is important to remove these particles 
because they can affect instrument hardware such as columns, flow lines, valves and frits (53). 
The efficiency of the filtration is determined by the porosity of the filter (58). Therefore, a lower 
porosity provides a cleaner extract but a longer filtering time. The membrane of fibers can be 
made of paper, glass, cellulose, or other plastic substances (58). The most common filtration 
systems operate under pressure differences and simply flow by gravity but there are more 
advanced micro-and ultra-filtration devices that require vacuum (53,58).  A popular filtration 
format is the 96-well flow through plate with an array of small membrane filters built as a 
sorbent bed (53).  It resembles the 96-well plates for solid-phase extraction and offers the same 
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benefit of simultaneous analysis of multiple samples at once (53).  With the 96-well filtration 
plates manufacturers offer various membranes and porosities to choose from (53). Depending on 
the application, filtration can be utilized as the only sample preparation method, or prior to an 
extraction method such as SPE.  An important consideration is to ensure the solvent is 
compatible with the filter and whether or not rinsings must be applied before and after applying 
the sample.  Furthermore, the analyst must be aware that adsorption of the analytes onto the filter 
or within the pores is possible.  
 1.5 Instrumental Analysis 
 
1.5.1 Liquid Chromatography  
Chromatographic separations are widely used in analytical toxicology prior to a detection 
mechanism. The goal of a separation technique is to obtain sharp, symmetrical peaks because 
then the sensitivity and selectivity are optimized. Liquid chromatography (LC) is the broad term 
used to describe any chromatographic procedure in which the mobile phase is a liquid. It is a 
widely used analytical separation technique because it can be applied to the separation of any 
compound that can be dissolved, and thus is amenable to a greater variety of compounds than 
GC (59). Furthermore, the complications of volatility, stability at high temperatures and 
derivatization are avoided by utilizing liquid chromatography compared to gas chromatography 
(59). Another added benefit is the increased control over separation efficiency because in LC you 
can manipulate both stationary and mobiles phases (59). The separation process in liquid 
chromatography is based on the differential distribution of sample components between a liquid 
mobile phase and a stationary phase which is fixed in place in a column (59-61). The separation 
between components is achieved as a result of differing attraction to the stationary phase. If the 
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component is strongly attracted to the stationary phase it will be retained which will delay its 
movement through the chromatographic system. In contrast, the components that are less 
attracted will be weakly retained and move more rapidly. Therefore, the migration rates of 
components will differ resulting in distinct, zones, bands, or peaks. There are many factors that 
influence the chromatographic separation, the most important being column efficiency (60). 
Column efficiency is used to compare column performance and is quantitatively measured by 
plate height and number of theoretical plates (60). The plate theory refers to a column made up 
of numerous discrete layers termed plates and at each plate equilibration of the component 
between the mobile and stationary phase takes place (60). As the number of plates increases, and 
the plate height decreases, the efficiency of the column becomes greater producing more narrow 
peaks (59-61). On the other hand, band broadening indicates a loss of column efficiency due to a 
slow rate of mass-transfer between the two phases (61). The parameters which affect column 
efficiency include diameter, length, and particle size of the column, flow rate and viscosity of the 
mobile phase, and type of stationary phase (59). Resolution describes the power of the column to 
separate the peaks of interest and is defined as the difference in their retention times relative to 
their widths (60). Consequently, the higher the resolution, the easier it is to obtain baseline 
separation between peaks, which is often achieved by lengthening the column (60). Columns for 
LC are available in many dimensions with regards to length, diameter, and particle size to suit 
the needs of the application. They range from short (50 mm) for high throughput to long (150 
mm) for greater resolution. Silica is commonly utilized for the particles because it can withstand 
high pressures and has a large surface area (59). The surface of the silica particles can 
subsequently be modified by chemical or physical means to produce stationary phases with 
different mechanisms of interaction. A decrease in particle size (<3µm) is effective because it 
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improves speed and resolution but a greater backpressure is produced. Ultra-High Performance 
Chromatography (UHPLC) refers to instruments that can operate at higher pressures and 
accommodate smaller particles sizes (60,61). The injection volume is another important factor to 
consider because it can impact peak shape and detection limits (60). If the injection volume is 
too large it can clog the column leading to peak broadening. Conversely, if the injection volume 
is too small it may be hard to detect the analytes but this problem can be overcome by 
incorporating an evaporation step to concentrate the analytes. LC can be divided into different 
modes or mechanisms based on the stationary phase used in the column. The most popular 
modes include reversed-phased, normal phase, and ion-exchange (60). The principles are the 
same as described in the previous section on solid-phase extraction. Reversed-phase 
chromatography is most commonly utilized, and consists of a non-polar stationary phase and 
polar mobile phase (60).  As a result, the most polar components elute first, followed by mid-
polar and then non-polar.  Reversed-phase chromatography is typically associated with a C18, or 
C8, which indicates the number of carbons on the alkyl chains, or a phenyl structure.  The more 
components in the sample the more likely it is that a gradient elution method will be used. 
Gradient elution refers to changing the mobile phase composition over time by increasing 
solvent strength (59-61). The benefit is sharper peaks, compared to when an isocratic method is 
used (59). Two to four mobile phase solvents are used and in reversed-phase A is the weaker 
solvent (water) and B is the stronger organic solvent (often ACN). It is important to use high-
quality-grade solvents that are compatible with the materials on the instrument. Unlike in GC, 
temperature does not have much of an effect on resolution in LC. However, an increase in 
temperature does reduce the viscosity of the mobile phase which increases the rate of mass 
transfer (61). Also, if the temperature is kept constant the chromatograms obtained are more 
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reproducible (61).  A chromatogram depicts the results of the separation and provides the 
retention time of each analyte which is defined as the time required for the analyte to reach the 
detector after injection (61). To conclude, the overall goal in LC method development is to 
optimize the separation of the components. It is important to choose the correct experimental 
conditions such as: the mode for the intended application, a column with high efficiency, the 
stationary phase chemistry, the length of the column, the composition of the mobile phase 
solvents, and the type of elution.   
 
1.5.2 Photodiode Array Detection (PDA)  
In most instances, a chromatographic method is combined with a detector to identify and 
quantify the eluted components.  A common combination is the use of LC with a UV/VIS 
detector which is based on the absorption of light in these regions. Therefore, a requirement is 
that substances should absorb strongly in the UV-visible region at different wavelengths or a 
chemical modification must be used to transform the substance into a derivative that can absorb 
(62). This is because the energy absorption properties of the substance are what is used to 
quantify the concentration in solution.  The relationship between the absorbance and the 
concentration of the absorbing analyte is known as Beer’s law (61-63). The equation for Beer’s 
law is shown below 
A=ℇ cl (61) 
 
 where A is the absorbance, ℇ  is the molar absorptivity which is characteristic of the substance 
and wavelength, c is the concentration of the solution and l is the path length of light through the 
solution (61). Based on this equation, concentration is linearly related to absorbance (62). 
However, it is a limiting law because at high concentration deviations from the linear 
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relationship can occur (61). As the concentration increases, the extent of solute-solvent or solute-
solute interactions can affect the analyte environment and may alter its absorptivity (61).  There 
are many variations for UV-Vis instrumentation, some are designed for operation in only the UV 
range while others operate in both the UV and VIS range (63). A UV/VIS spectrometer consists 
of five essential components: a light source, a monochromator, sample container, detector, and a 
readout device (61,62).  For UV, the light source is commonly a deuterium lamp, the 
monochromator provides wavelength selection, and the sample container or sample format must 
be transparent so the light can pass through (61). The light that is transmitted is quantified by the 
detector which produces an electrical signal when it is struck by the photons (62). There are 
different types and designs of detectors which consist of a photon transducer which can be in the 
form of photovoltaic cells, phototubes, photomultiplier tubes, or photodiodes (61). The signal 
from the detector is then amplified and converted to readable form that is displayed on a 
computer. There are three types of multichannel detectors used in spectroscopic instruments: 
photodiode arrays, charge-injection devices, and charge-coupled devices (61). 
With regards to photodiode array detection, after the light passes into the monochromator it is 
dispersed onto a photodiode-array transducer, which consists of a linear array of several hundred 
photodiodes mounted on a silicon chip (62). The slit of the monochromator is identical to the 
width of one of the diodes, as a result, each diode receives a different wavelength (62). The 
outputs from the diodes are scanned rapidly and sequentially which allows for the simultaneous 
measurement of multiple wavelengths and collection of the entire absorbance spectrum (62). The 
resulting data is a plot of absorbance as a function of wavelength.  Identification of a component 
is based on the combination of both retention time and UV spectrum. For quantification, it is 
important to select the wavelength where the analyte demonstrates maximum absorption because 
21 
 
this will increase sensitivity (62,63). Once an appropriate wavelength is selected, peak areas are 
integrated which are proportional to the amount of the analyte in the sample. Interferences will 
arise only if compounds co-elute with the analyte and absorb radiation in the same spectral 
region as the analyte. There are many advantages to using PDA detection which include: 
robustness, reproducibility, lower operating costs than MS instrumentation, simple design which 
needs minimal maintenance and no recalibration (61-63). It allows monitoring a sample at more 
than one wavelength and peak purity analysis (61). Lastly, when coupled to LC it provides useful 
qualitative and quantitative information for multiple compounds in a single run. 
 
1.5.3 Quadrupole-Time-of-Flight-Mass Spectrometry (Q-TOF-MS) 
Another detection system often coupled with UHPLC is mass spectrometry (MS) which offers 
increased sensitivity and selectivity for both qualitative and quantitative analyses. In recent 
years, technological advances have enabled the development of various ionization mechanisms 
and mass analyzers, making MS a very flexible detection system with various applications. MS 
detection can provide elemental and structural information by means of molecular weight 
determination, fragmentation patterns, and isotope ratios (64). A basic mass spectrometer has 
five components: a sample inlet; to introduce the sample into the MS, an ionization source; 
where the sample molecules are ionized, next is the mass analyzer; which separates the ions 
based on their mass-to-charge-ratio (m/z), then a detector records and counts the ions and finally 
a data processing system plots and manipulates the data to produce a mass spectrum (65). A 
mass spectrum provides the results as a plot of ion intensity versus m/z. The most intense peak 
called the base peak is assigned an intensity of 100 and all other peaks are assigned an 
abundance relative to the base peak (65). The type of ionization method utilized depends on the 
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separation step (GC, LC or CE), the nature of analyte, the information required, and the 
capabilities of the instrumentation. The various ionization methods include: electron impact 
ionization (EI), chemical ionization (CI), electrospray ionization (ESI), atmospheric pressure 
chemical ionization (APCI), and desorption ionization techniques. EI and CI are commonly used 
with GC, and ESI and APCI are commonly used with LC, whereas desorption ionization 
techniques are often used for larger biomolecules and involve in-situ analysis with no prior 
separation (64).  The most well-known and simple method to ionize the sample is EI. In EI, the 
sample which is in vapour phase is bombarded by a beam of electrons emitted from a filament 
(64,65). The high-energy bombardment causes the molecules to become ionized by the loss an 
electron, excited and then relax which often occurs by fragmentation to produce ions of lower 
masses (61,64,65). The ionized molecule that loses an electron but does not undergo 
fragmentation forms a positively charged molecular ion (M+) which has the same molecular 
mass as the analyte of interest and appears at the highest value of m/z on the spectrum 
(61,64,65). The ionized molecules are directed to the mass analyzer based on a potential 
difference between two plates where they are sorted according to their mass-to-charge ratios 
which are then displayed in the form of a mass spectrum (61,64,65). EI is a “hard” ionization 
method meaning it leads to significant fragmentation (61). However, the fragmentation pattern is 
characteristic of the analyte and reproducible so it is useful in identification (61,64). 
Electrospray ionization (ESI) takes place under atmospheric pressure and temperature and is 
tailored to ionize molecules from liquid streams, thus, samples are directly introduced from 
UHPLC (1,64). In ESI, a solution of sample is passed through a stainless steel capillary needle 
held at high voltage potential, creating charged droplets that are expelled into the ionization 
chamber (1,64).  The charged droplets come in contact with a nebulizing inert gas that disperses 
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the liquid into an aerosol (1). As the solvent evaporates from the droplets, their charge density 
becomes greater until the surface tension can no longer support the charge and they break apart 
into smaller droplets (64). This process continues until all the solvent evaporates and the charge 
is transferred to the analyte (64). The ions are then drawn towards the mass analyzer by an 
electric field (64). Ions formed can be positive or negative and modern ESI sources can be 
programmed to analyze in positive or negative mode depending on the application (64). 
Furthermore, the fragmentation parameters can be optimized by running a standard solution at 
different voltage, pressure, and temperature settings. A concern in LC/MS techniques is the 
possibility of ion suppression. Ion suppression can occur when excessive ions are produced from 
the sample and the signal from the analyte of interest is suppressed in the background noise (1).  
This can arise from concentrated analytes, the matrix, solvents, or glassware and can negatively 
affect the limit of detection, precision and accuracy of the results. Therefore, it is important to 
examine the method for the presence of ion suppression and try to minimize it.  Also, the 
formation of adducts is possible but can be controlled by using highly pure mobile phase 
solvents (1).  
As mentioned previously, several different mass analyzers are available for separating ions. With 
regards to the quadrupole-time-of-flight mass spectrometer (Q-TOF-MS), there are two different 
mass analyzers combined; the quadrupole and time-of-flight analyzer. The performance of the 
mass analyzer is measured according to its mass range limit, its analysis speed, the ion 
transmission rate, its mass accuracy and its resolution (65).  The term quadrupole refers to a 
linear quadrupole designed with rods arranged in parallel and opposite (64). It operates by 
varying two electrostatic fields, one direct current and one radio frequency which creates a 
resonance frequency for each m/z value (64).  Therefore, only ions of a specified m/z pass 
24 
 
through the quadrupole and reach the detector. The full mass range can be scanned so that ions of 
sequential m/z pass through the analyzer or it is possible to operate the quadrupole so that only 
ions with a certain m/z pass through, this is called selected ion monitoring (64,65).  
A time-of-flight mass(TOF) analyzer functions on the relationship between kinetic energy, 
velocity and mass. Ions produced are accelerated into a flight tube by an electric field pulse 
ensuring all the ions entering acquire the same kinetic energy (61,64). Since the ions have the 
same energy, they will travel through the tube at different speeds due to differences in mass 
(64,65). Separation by mass occurs, with the lighter particles arriving at the detector before the 
heavier ones (64). The mass-to-charge ratios are determined by measuring the time it takes for 
the ions to arrive at the detector (64).  A TOF analyzer can measure an analytes mass to four 
decimal places providing accurate mass measurement. Thus, many different drugs or metabolites 
with close molecular masses can be effectively separated due to mass determination with high 
accuracy.  The added advantage of the quadrupole as a scanning device allows for accurate mass 
measurement of precursor and fragment ions for increasing specificity and sensitivity.  
1.6 Method Validation 
The accuracy and reliability of analytical data is very important in forensic toxicology for the 
correct interpretation of findings. If unreliable scientific data is entered as evidence, serious legal 
implications could result. Therefore, it is crucial that method validation is performed to ensure 
the analytical measurements obtained are reliable, precise, and consistent so that the method’s 
performance is acceptable for its intended use. It is also important for recognizing the method’s 
limitations.  An analytical method needs to be validated or revalidated in the following 
examples: a new method is developed, an existing method does not meet current validation 
requirements, the method is transferred to another laboratory, modifications of an established 
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method such as adding new compounds or to demonstrate equivalence when switching to a new 
instrument (66-68). The requirements for method validation in forensic toxicology have been 
defined in different working groups and committees such as The American Academy of Forensic 
Sciences (AAFS), The Scientific Working Group for Forensic Toxicology (SWGTOX), The 
American Board of Forensic Toxicology (ABFT), and the Society of Forensic Toxicologists 
(SOFT). These organizations provide documents outlining the standards for method validation 
and information pertinent to understanding the parameters and definitions. Laboratories are 
responsible for choosing which standard of practice to follow and implementing a validation 
plan.  Analytical method validation is the process of performing a series of validation 
experiments that statistically evaluates the efficacy, reliability, and applicability of a method (66-
68). The type and extent of validation experiments depends of the scope of the method for 
example, whether it is used for screening, qualitative, or quantitative purposes (66-68). For a 
proper validation plan, it is important to outline the validation parameters that should be 
evaluated and their corresponding acceptance criteria.  In forensic toxicology, there is general 
agreement that the following parameters should be examined: precision, accuracy, linearity, 
stability, limit of detection, and each are described below (66-68).  
Precision 
Precision refers to the degree of closeness between a series of measurements when a procedure is 
applied to multiple replicate samples (66-68).  Precision should be evaluated for each 
concentration using at least three different samples over five different runs (66-68). Therefore, 
intraday precision and interday precision should be assessed and under the same operating 
conditions each time. It is calculated as the coefficient of variation (%) and should be within 
20% (66-68). However, acceptance criteria can vary depending on the matrix, certain matrices 
may require better reliability and thus a lower CV (66-68).  
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Accuracy 
It is the closeness of agreement between the measured experimental value and the theoretical 
value (66-68). Accuracy is determined by blinded analysis of standard samples with known 
concentrations and is described as bias studies (66-68).  It should be measured using triplicate 
samples at a minimum of two concentration levels (low and high) (66-68). It is calculated as a 
percent deviation from the theoretical value using the equation: mean measured concentration-
theoretical concentration/theoretical concentration) x 100% (66-68). The maximum 
recommended acceptable bias is within 20% of the true value (66-68).  
Limit of Detection 
This is the lowest concentration that is detectable and differentiated from the background noise 
but not subject to precision criteria (66-68). It needs to yield a peak with a height greater than or 
equal to three times the baseline noise level from the negative control (66-68).  
Limit of Quantification (LOQ) 
The lowest concentration that can be quantitatively determined with acceptable precision (66-
68). The selected concentration should have a precision that does not exceed 20% (66-68). A 
signal-to-noise approach can also be applied where the signal-to-noise ratio is required to be 
equal to or greater than 10 (66-68).  
 
Linearity (Calibration Curve Model) 
Linearity is evaluated as the relationship between detector response and concentration. A 
calibration curve is plotted to demonstrate that response is directly proportional to the 
concentration (66-68).  The concentration range chosen should reflect the concentrations you 
would expect in the matrix of interest (66-68). It is ideal to have at least six non-zero 
concentrations covering the expected range (66-68). The resulting curve is usually graphically 
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displayed and evaluated for linearity by calculating the regression line (66-68). The most 
common indicator utilized is the correlation coefficient (>0.99) (66-68). In some cases, it is 
possible that the relationship is modelled more effectively with a quadratic regression rather than 
a linear regression.  
 
Stability 
Method validation must include stability experiments for the various stages of analysis and the 
conditions used should reflect situations likely to be encountered during sample handling, 
storage and analysis. Stability experiments should evaluate long-term storage (frozen), short-
term storage (room-temperature), freeze-thaw stability, and under conditions of analysis ( sample 
preparation stability, autosampler stability) (66-68). The experiment should be designed to 
analyze samples at both low and high concentrations for preselected time intervals that cover the 
expected maximum time (66-68). The response at time zero is compared to the response from 
each time interval to see if there was any change in response.  
Additional validation parameters that may be investigated depending on the application and 
instrumentation used are: carryover, dilution integrity, recovery, and matrix effects.  
Internal standards are also a very important factor in obtaining accurate and reliable quantitative 
results.  It improves precision and accuracy of the method because the effect from sources of 
error are minimized. The internal standard should have chemical and physical properties that are 
very close to the analyte, and as a result behave similarily, but are well-resolved and produce a 
signal that can be distinguished from all analytes (2). Therefore, any factors that affects the 
internal standards will also affect the analytes to the same degree. This is important because the 
internal standards serve the purpose of correcting for any differences in extraction efficiencies, or 
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variations that might result from small errors during handling or preparation of the samples (2). 
Quantification is based on the ratio of response between the analyte and IS (2). Since both 
compounds will undergo the same losses their ratio will remain unchanged during the procedure. 
For GC/MS or LC/MS procedures it is very common to use deuterated internal standards (1).  
 1.7 Drug Detection in Bone 
Although blood is typically the matrix of choice in post-mortem forensic toxicology, the use of 
other biological matrices may be necessary in cases where blood is unavailable. For example, in 
cases of extreme decomposition, where only skeletonized remains exist, bone may be the only 
suitable matrix for analysis. For many years, researchers have been trying to determine whether 
drugs can be detected in bone and if they are detected whether the levels can be accurately and 
quantitatively interpreted. Therefore, the main question is: do drug levels in bone samples 
correlate to the blood concentrations at time of death (69-71)? So far, a general agreement on the 
answer to this question has not been reached. There are instances where a correlation between 
bone and blood concentrations was demonstrated and other instances where correlations prove 
non-significant (70,71). The issues that may cause the discrepancies are: drug deposition and 
distribution in bone, differences in sampling location, and the use of animal models (69-71)  
There are several factors that can influence the deposition and distribution of drugs in bone and 
bone marrow, such as bone type, physicochemical characteristic of the drug and metabolites, 
drug exposure (acute vs chronic) and distribution at the time of death (69) The mechanisms 
involving drug deposition in bone are not fully understood, therefore, studies should be 
conducted using different drugs, exposure types, and environmental conditions. A variety of 
bone types have been analyzed in the literature and in our laboratory and the results demonstrate 
that depending on the specimen chosen (femur, vertebrae, tibia etc.) the drug levels can vary (70-
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82) In the literature, several articles describe the analysis of bone or marrow and generally 
involve the same steps of dissection to remove tissues, washing and drying, extraction of the 
drugs from the bone using an organic solvent followed by analysis of the supernatant (70,71) 
Furthermore, multiple drug classes have been detected in bone such as benzodiazepines, 
stimulants, antipsychotics, opioids, and tricyclic antidepressants (70-82). Thus, common drugs 
may be detected in bone using current methods which proves bone may be a useful alternative 
specimen to blood. However, caution must be exercised because most studies have been 
conducted on animal models and application of the data obtained to human autopsy cases 
requires careful consideration. In our laboratory, we conduct studies using controlled drug 
exposure in experimental animals with the hopes of establishing standardized methods and a 
reference database for bone drug measurements.  Thus far, the work of Watterson and colleagues 
has demonstrated interesting findings with regards to detection of drugs in bone such as 1) there 
is substantial variation in drug and metabolite levels between bone types, 2) the vertebral, pelvic 
and femoral bone exhibit the largest drug levels, 3) the measurement of the ratio of the 
metabolite-to-parent drug levels show less variability than individual drug concentrations across 
different bone types 4) drug exposure may be distinguished based on the ratio of levels of parent 
to metabolite and 5) body position and microclimate influence drug levels (72-81).  The findings 
illustrate there are many factors to consider when interpreting toxicological analysis of bone 
making it a challenge.  In the future, as the research in this field continues, validated 
standardized methods will be implemented, and eventually quantitative interpretation will be 
achievable.  
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Chapter 2 
 
Characterization of degradation products of selected phenothiazine drugs formed during a 
standard SPE approach is described. This project was intended to develop an analytical method 
for promethazine (PMZ), chlorpromazine (CPZ) and their respective N-desmethyl and sulfoxide 
metabolites in biological samples (bone tissue extract and blood) by UPLC-PDA, using mixed-
mode SPE for basic drugs, using ethyl acetate:isopropanol:ammonium hydroxide (80:18:2) as the 
elution solvent. During the validation process, extraneous peaks were observed that were absent 
in the negative control. Analysis of extracts of PMZ and CPZ individually yielded extraneous 
peaks, including peaks with retention time and UV spectra suggesting the formation of the 
sulfoxide metabolites, amongst others. With the hypothesis that the analytes were being oxidized 
during the sample preparation process, each analyte was extracted individually and analyzed by 
UPLC-qTOF-MS using the same chromatographic column and mobile phase program. The 
resulting data supported that hypothesis, as we confirmed through analysis of reference standards 
that PMZ was being oxidized to its corresponding sulfoxide and N-oxide while CPZ was 
oxidized to its corresponding sulfoxide. Therefore, the oxidation products included naturally 
occurring metabolites of the drugs being assayed. Oxidation was also observed in analysis of 
whole blood, and thus not specific to bone tissue extract. To minimize oxidation, SPE using a 
different elution solvent was evaluated, as was filtration/pass through extraction (FPTE) with and 
without evaporation.  The results demonstrated that the sample preparation method highly 
influence the extent of oxidation.  FPTE without an evaporation step was the only method that 
did not measurably induce analyte oxidation.  The method was validated for the analysis of 
PMZ, CPZ and their corresponding metabolites in bone tissue extract by UPLC-qTOF-MS 
according to SWGTOX standards.  
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2.1 Introduction 
 
 Methods for extraction of basic drugs from postmortem tissue samples are often based on liquid-
liquid extraction (LLE) (82,83) or solid-phase extraction (SPE) (83,84), in order to provide 
sufficiently clean extracts so that they may be analyzed by GC/MS or HPLC with optical 
detection, or to reduce matrix effects in methods based on LC/MS/MS. Work in our laboratory is 
focused on analysis of drugs and metabolites in skeletal remains. Following a solvent extraction 
procedure to extract analytes from the bone matrix, SPE-based methods generically designed for 
basic drugs, with minor variations to improve cleanliness or recovery, are used to assay a range 
of analytes (85,86,87). At the onset of this work, we sought to examine the relative distribution 
of two basic drugs from the same class (phenothiazines) in skeletal tissues, with the intent of 
investigating the effect of slight structural differences on the relative distribution of each drug 
and its metabolites across the skeleton. 
   Herein, we describe our initial efforts to validate a method for the analysis of promethazine, 
chlorpromazine and their respective N-desmethyl and sulfoxide metabolites in skeletal remains 
using UPLC-PDA. Throughout the validation efforts, evidence of analyte degradation occurring 
during the sample preparation process was observed. Here, we describe our characterization of 
the extent of the degradation, data collected to identify the degradation products by UPLC-PDA 
and UPLC-qTOF-MS, and the influence of modifications to the extraction process on the extent 
of oxidation. Lastly, we developed and validated a simple sample preparation method for the 
analysis of promethazine, chlorpromazine and corresponding metabolites that does not induce 
any measurable oxidation of the analytes.  
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2.2 Materials and Methods 
 
2.2.1 Chemicals  
 
   Promethazine (PMZ), chlorpromazine (CPZ), desmethylpromethazine (DPMZ), 
desmethylchlorpromazine (DCPZ), promethazine sulfoxide (PMZSO), chlorpromazine sulfoxide 
(CPZSO), promethazine N-oxide (PMZNO) and internal standard Promazine (PZ) were 
purchased from Toronto Research Chemicals (Toronto, ON). The internal standards 
promethazine-d3 and chlorpromazine d-3 were purchased from Cerilliant (Round Rock, TX, 
USA).  Methanol (MeOH) and acetonitrile (ACN) used in sample preparation and extraction 
were both HPLC grade, and obtained from EMD chemicals (Gibbstown, NJ).  and J.T Baker 
(Center Valley, PA), respectively.  For UHPLC-PDA mobile phase, high-performance liquid 
chromatography (HPLC)-grade water was obtained through a Milli-Q water purification system. 
ACN and formic acid used for UPLC-PDA mobile phase was LC/MS grade and obtained from 
Fisher Scientific.  For UHPLC-QTOF-MS mobile phase and washes, Acetonitrile (ACN), 
methanol (MeOH), and water were all LC/MS grade and purchased from OmniSolv (EMD, 
Millipore). Leucine enkephalin is used as a reference material and is obtained from Waters 
Corporation (Milford, MA).   
2.2.2 Sample Preparation  
 
2.2.2.1 Solid Phase-Extraction (SPE) 
 
  The analytical matrix used in method validation was bone tissue extract (BTE), prepared by 
subjecting samples (1 g) of drug-free decomposed bone to microwave-assisted extraction in 5 ml 
of methanol and then reconstituting in 1ml of phosphate buffer (PBS 0.1M, pH 6). Each sample 
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was prepared in 1 mL of BTE, using 500 ng of promazine as internal standard. Lipids and 
proteins were precipitated by addition of 3 mL of ACN:MeOH (1:1) followed by storage at -20 
o
C overnight. Samples were centrifuged for 10 min (4000 rpm) and the supernatant was collected 
and evaporated to 1 mL using a Centrivap vacuum concentrator (Labconco, Kansas City, MO, 
USA). Following evaporation, samples were diluted with 2 mL of PBS and then acidified with 
100 L of glacial acetic acid prior to solid phase extraction (SPE).  
   Samples underwent SPE using Clean Screen XCEL I (130 mg) 48-well plates (United 
Chemical Technologies, Bristol, PA).   Wells were conditioned using sequential additions of 3 
mL MeOH, 3 mL water, and 3 mL of PBS. After loading samples by gravity, wells were washed 
with 3 mL of PBS,  followed by 3 mL of 0.1 M acetic acid.  Wells were then dried under vacuum 
(~350 mmHg) for 5 min. After drying, wells were washed with 3 mL of MeOH and then 
sorbents were dried for a second time under vacuum for 10 min (~350 mmHg). Two different 
elution solvent systems were used: a solvent mixture based on dichloromethane (DCM), 
consisting of DCM:isopropanol:ammonium hydroxide (80:17:3) or one based on ethyl acetate 
(EA) consisting of EA:iPrOH:NH4OH (80:17:3). Extracts were then evaporated to dryness at 40 
o
C by vacuum centrifugation and reconstituted in 500 L of mobile phase A (0.1 % formic acid 
in 90:10 water:ACN). Samples were centrifuged for 10 min at 13,000g and then transferred to 
autosampler vials, and 15L of sample was injected into the UPLC.  
2.2.2.2Filtration/Pass-Through Extraction (FPTE) 
 
   Samples were prepared in 500 L of BTE and underwent protein precipitation by addition of 1 
mL of (ACN:MeOH, 1:1). Following incubation at -20 
o
C overnight, the samples were 
centrifuged at 4000 RPM and then poured directly into wells of the FASt 96-well plate (United 
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Chemical Technologies, Bristol, PA). After filtration, the samples were collected, evaporated to 
dryness by vacuum centrifugation, reconstituted in 500 L of mobile phase and centrifuged for 
10 min at 13,000 RPM. Samples (2 L) were injected for instrumental analysis following the 
same parameters mentioned above.  
2.2.2.3 FPTE without Evaporation 
 
   The stock solutions were prepared in 1ml of BTE. A 200L volume was removed from the 
stock solutions and transferred to clean test tubes where 800L of ACN:H2O (1:1) was added 
for a final volume of 1mL. The internal standards were added, the samples were vortexed and 
then poured directly into the wells of a FASt 96-well plate. Once the samples were filtered, they 
were collected and centrifuged for 10 min at 13,000g. After centrifugation, the samples were 
transferred from microcentrifuge tubes to autosampler vials, and 2L of sample was injected 
into the UPLC. 
2.2.3 Characterization of Analytical Performance – UPLC-PDA of SPE Extracts 
 
   The criteria followed in initial efforts to validate the method were based on the guidelines set 
forth by the Scientific Working Group For Forensic Toxicology (SWGTOX). Standard analyte 
samples were prepared in 1 mL of BTE at concentrations ranging from 0 to 10,000 ng/mL in 
triplicate. Standard curves were prepared on five different days from extracted standards to 
assess precision, linearity, accuracy, and limits of detection and quantification (LOD and LOQ).  
2.2.4 Method Validation – FTPE without Evaporation and UPLC-qTOF-MS 
 
   The criteria followed to validate the final method were consistent with the guidelines set forth 
by the Scientific Working Group For Forensic Toxicology (SWGTOX). Standard analyte 
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samples were prepared in 1 mL of BTE at concentrations ranging from 0 to 2,000 ng/mL in 
triplicate. Standard curves were prepared from extracted standards to assess precision, 
concentration dependence, accuracy, matrix effect, recovery and limits of detection and 
quantification (LOD and LOQ). The concentration dependence of six non-zero concentrations 
over the concentration range 10-2000 ng/mL was assessed by plotting the best-fit (R
2
 ≥0.99) of 
peak area ratios versus concentration. The intraday and interday precision was measured as the 
coefficient of variation (CV), of triplicate analyses over the assayed concentration range on five 
different days. Accuracy was determined through blinded analysis of triplicate samples at two 
different concentrations of each analyte, the measured concentration must be within 20% of the 
theoretical concentration. The limit of detection for a given analyte was defined as the lowest 
concentration assayed with S/N ≥3, but not subject to precision criteria, while the limit of 
quantification (LOQ) for a given analyte was defined as the lowest concentration assayed where 
precision (CV) was ≤ 20%.  The matrix effect (ion enhancement or suppression experienced by 
analytes in an extract) was determined by the post-extraction spike method and was evaluated at 
three concentrations levels: low (25 ng/ml), mid-range (100 ng/ml), and high (1000 ng/ml). The 
response of the analyte in standard solution was compared to the response of the analyte spiked 
into a blank matrix sample that underwent the sample preparation process.  It was calculated as 
the response of the post-extracted spiked sample divided by the response of the non-extracted 
neat sample, minus one * 100%. Analyte recovery was defined as the ratio of analyte peak area 
in an extracted sample to the peak area of that analyte, spiked at the same nominal concentration, 
into a drug-free, matrix-matched extract.  
2.2.5 Ultra-Performance Liquid Chromatography (UPLC) Conditions 
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   An Acquity
TM
 UPLC equipped with a photodiode array detector (UPLC-PDA; Waters Corp., 
Milford, MA) or with a quadrupole time-of-flight mass spectrometer ((UPLC-QTOF-MS; 
Waters Corp., Milford, MA)  was used for the analysis of extracts. The column used was a 
Raptor biphenyl column (150 mm  2.1 mm, 2.7 μm particle diameter; Restek, Bellefonte, PA) 
with column temperature set to 50 
o
C. A binary gradient elution (A: 0.1 % formic acid in 90:10 
water:ACN and B: 0.1% formic acid in 90:10 ACN:water) was used. The gradient was as 
follows: 95:5 A:B held for 1 min, linear increase to 70:30 A:B over 4 min and held for 1 min; 
linear increase to 20:80 A:B over 3 min; reversion back to 95:5 A:B, for 1 min. The total run 
time was 10 min with a constant flow rate of 0.300 mL/min and the injection volume was 15 L. 
The wavelength range was set from 210 to 400 nm, and for quantitative comparisons, the 
sulfoxide metabolites were monitored at 240 nm, while the remaining analytes were monitored at 
250 nm. Data acquisition was performed using Waters MassLynx software version 4.1.  
2.2.6 UPLC-TOF MS Settings and Conditions 
 
   Mass spectrometry was performed on a Waters Acquity UPLC equipped with a Waters Xevo 
G2-XS-qTOF (Waters Corp., Milford, MA). Data was acquired in sensitivity mode under 
positive electrospray ionization with resolution > 20,000 at full width half maximum. The 
acquisition range was from m/z 50 to 601, using a scan time of 0.1 sec. Capillary voltage and 
cone voltage were set to 0.5 kV and 25 V, respectively.  The source temperature was 150 
o
C, the 
desolvation gas flow was set to 1000 L/hr at a temperature of 500
 o
C and the cone gas was set to 
50 L/hr. Data acquisition was achieved using MS
e
 mode, with low collision energy set to 6.0 eV, 
and the high-energy ramp ranged from 10-40 eV. Nitrogen was used as both the drying and 
nebulizing gas and the collision gas was argon. Verification of calibration of the mass axis from 
m/z 50 to 601 was conducted daily with 5 mM sodium formate. Leucine enkephalin was used as 
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the lockmass reference compound in positive mode at m/z 278.2641 and infused at a flow rate of 
10 L/min. MassLynx® Software (version 4.1) was used for data acquisition and processing.  
 
2.2.7 Autosampler Stability 
 
   The stability of analytes while on the instrument autosampler (maintained at 25 
o
C) was 
evaluated on the UHPLC-PDA by repeated injection of the extracted samples at two different 
concentration levels (100 ng/mL and 2000 ng/mL, n=3) for 0, 6, 12, 18, 24, 30, 36 hr. Analytes 
were considered stable if there was no deviation in analyte response in excess of 20% from the 
response of the corresponding sample at t=0 hr. Autosampler stability was also assessed on the 
UHPLC-Q-TOF-MS by repeated injection of extracted analytes analyzed individually at two 
different concentration levels (100 ng/mL and 1000 ng/mL per analyte, n=3) after 0, 12,  24 and 
36 hr incubation. Analytes were considered to be stable if there was no deviation in analyte 
response more than 20% from the response of the corresponding analyte at t=0 hr.  
2.3 Results 
 
2.3.1 Characterization of Analytical Performance – UPLC-PDA 
 
   Analytical performance data for UPLC-PDA analyses are summarized in Table 2. The 
response ratio was linear (R
2
>0.99) from 25 ng/mL to 10,000 ng/mL for all analytes.  Analytical 
precision (CV) ranged from 0.9%-30% for PMZ and its metabolites (PMZSO, DPMZ), and from 
0.8%-29% for CPZ and its metabolites (CPZSO, DCPZ). While precision criteria were not met 
in all cases, the data in Table 2 indicate that CV values in excess of 20% were observed in 5 or 
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fewer cases of a total of 90 different sets of triplicate extractions for PMZ and its metabolites, 
and in 6 or fewer cases for CPZ and its metabolites.  
 
   Accuracy (bias) was assessed through blind analysis of standard samples prepared in BTE at 
concentrations ranging from 150 to 2000 ng/mL. Bias was acceptable when the measured 
concentration deviated from the target concentration by no more than 20%. For PMZ and 
metabolites, the deviation range was -101% to 48% and for CPZ and metabolites was -36% to 
23%. While accuracy criteria were not strictly met, the data in Table 2 indicate that absolute bias 
values in excess of 20% were observed in 8/90 cases or less for PMZ and its metabolites, and in 
no more than 6/90 cases for CPZ and its metabolites. 
   The stability of the analytes while resident on the autosampler tray was assessed at two 
different concentrations over a 36 hour time period. For all analytes, there was no change in 
response ratio in excess of 20% of the initial response (t=0 hr), indicating that they remained 
stable while on the instrument waiting to be run.  
Table 2: Summary of validation parameter results (LOD, LOQ, precision, linearity, bias). Solid-
phase extraction with ethyl acetate elution solution was used as the sample preparation method 
and a UPLC-PDA as the analytical instrument. Data were collected over 9 different sets of 
extractions of analyte standard mixtures ranging from 25-10,000 ng/mL, where each standard 
concentration was analyzed in triplicate. 
Analyte Retention 
Time 
(min, 
±0.05) 
Limit of 
Detection 
(LOD, 
ng/mL) 
Limit of 
Quantitation 
(LOQ, 
ng/mL) 
Precision 
(CV, %) 
(Acceptance 
Criteria: ≤ 20%) 
 [# failed] 
Linearity 
(Acceptance 
Criteria: 
R
2≥0.99) 
Bias (%) 
(Acceptance 
Criteria: ≤ 20%) 
[# failed] 
PMZ 7.13 10 25 0.9-22.6 [5/90] 0.9990 -0.3-(-101.4) 
[8/90] 
39 
 
PMZSO 4.32 10 25 0.4-30.0 [5/90] 0.9986 -0.9-(-44.0) 
[6/90] 
DPMZ 6.76 10 25 0.9-18.8 [2/90] 0.9987 0.8-(-18.1)  [5/90] 
CPZ 8.09 10 25 1.8-22.2  [2/90] 0.9994 0.1-(-23.6)  [1/90] 
CPZSO 5.32 10 25 0.8-29.2 [6/90] 0.9932 0.5-(-36.5)  [6/90] 
DCPZ 7.95 10 25 1.7-21.7% [3/90] 0.9988 -0.3-( 30.5) [2/90] 
 
2.3.2 Appearance and Putative Identification of Extraneous Peaks in 
Chromatograms of Extracted Standards 
 
   A closer examination of the chromatograms from extracted standards revealed extraneous 
peaks that were not present in the negative control or unextracted standard mixture. Four minor 
chromatographic peaks (labeled 1-4) and drug standard peaks were detected in the 
chromatograms as shown in Figure 5. We first considered whether the extra peaks were the result 
of impurities in the solvents used in extraction or mobile phases. In analysis of multiple 
unextracted standard mixtures, analyte-free samples of mobile phase A and samples of extraction 
reagents that had been evaporated and reconstituted in mobile phase A, no extraneous peaks 
were observed.   We then hypothesized that analytes were undergoing chemical degradation 
under the sample preparation conditions used. To determine which analyte was generating each 
extraneous peak, analyte standards were extracted from BTE individually (ni=3). 
Chromatograms of extracted standards of PMZ and CPZ produced multiple extra peaks that were 
not present in the drug-free negative control, as shown in Figures 2 and 3.  The peaks labeled 1, 2 
and 3 from Figure 6 had retention times of 4.62 min, 4.70 min, and 7.59 min, respectively. The 
retention time of peak 2 from Figure 6 and peak 1 from Figure 3 (4.70 min and 5.32 min, 
respectively), from each extracted sample corresponded to the same retention time as PMZSO 
and CPZSO, respectively, and the UV spectrum of each sulfoxide standard was indistinguishable 
from the UV spectrum of the corresponding extraneous peak (Figs. 6-7). These results support 
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the putative identification of the compounds corresponding to peak 1 (Fig. 7) and peak 2 (Fig. 6) 
as chlorpromazine sulfoxide and promethazine sulfoxide, respectively. 
 
 
 
 
 
Figure 5: (C-E) UHPLC-PDA chromatograms (240nm, 4.50-9.00 min window) of extracted 
standards (n=3) at a concentration of 2000 ng/ml. Extraneous peaks are labeled 1-4. (A) 
Unextracted analyte standard mixture for retention time verification. (B) Drug-free negative 
control. 
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2.3.3 Confirmation of Extraneous Products by UPLC-TOF-MS: Phenothiazene 
Oxidation 
 
   In order to confirm that PMZ and CPZ were being oxidized to their corresponding sulfoxides, 
high resolution mass spectral data was acquired. The same set of individually extracted standards 
was analyzed by UPLC-qTOF-MS using the same column and chromatographic method to 
obtain accurate mass measurements for the compounds corresponding to the extraneous peaks. 
These data served as additional parameters for characterization and identification. The 
extraneous peaks that were observed in the chromatograms from the UPLC-PDA (Figs. 6 and 7) 
were also observed in the total ion chromatograms (TICs) from the UPLC-q-TOF-MS (Fig. 8). 
The TIC for the extracted PMZ sample indicated the presence of compounds eluting at 4.71 min, 
4.81 min, and 7.7 min with measured masses of 317.1356, 301.1355, and 301.1426 Da, 
respectively (Fig. 8C, 8MS-C). The TIC for the extracted CPZ sample indicated the presence of 
compounds eluting at 5.45 min, 5.82 min, 6.18 min and 8.23 min with measured masses of 
335.1017, 351.1020, 376.1273, and 335.1054 Da respectively (Fig.  8D, 8MS-D). The accurate 
mass data is summarized in Table 3. For both extracted PMZ and CPZ samples, two of the 
extraneous peaks had the same accurate mass but differed in retention time. If we consider the 
accurate mass (M) measured for the parent drug molecules (285.1419 Da for PMZ and 319.1090 
Da for CPZ), a pattern of M+16 or M+32 was observed for the mass of the extraneous 
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compounds, suggesting the occurrence of oxidation (Fig. 7, Table 3).  As expected, comparison 
of the results with reference material indicated that PMZ was oxidized to its corresponding 
sulfoxide (Peak 2) and N-oxide (Peak 3) while CPZ was oxidized to its corresponding sulfoxide 
(Peak 1). The PMZNO standard was acquired after the samples had been analyzed to confirm the 
identity of peak 3 in Figure 8C and as a result, is not included in the chromatograms for 
unextracted standard mixtures shown in any of the figures. Where reference standards were 
available, the parameters used for compound identification were retention time, accurate mass 
and fragmentation pattern. Possible candidates for the remaining oxidation products based on 
accurate mass data include the sulfone, sulfoxide-N-oxide or hydroxylated form of the parent 
drug.  
 
Table 3:  Summary of accurate mass data for labeled peaks in Figs. 4 and 5. 
Extracted Promethazine Standard (Fig. 4) Extracted Chlorpromazine Standard (Fig. 5) 
Compound Accurate Mass 
(±0.005) 
Compound Accurate Mass 
(±0.005) 
Peak 1 317.136 Peak 1 335.102 
Peak 2 301.136 Peak 2 351.102 
Peak 3 301.143 Peak 3 376.127 
Promethazine 285.142 Peak 4 335.105 
Chlorpromazine 319.109 
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Figure 6:(A) Unextracted analyte standard mixture for retention time verification. (B) Drug-free 
negative control. (C) UHPLC-PDA chromatogram (240 nm, 4.5-9.0 min window) of 
promethazine standard prepared at a concentration of 1000 ng/ml in BTE, and extracted by SPE. 
Extraneous peaks are labeled 1-3. UV absorbance spectrum associated with peak 2, retention 
time of 4.70 min is compared to the spectrum of a PMZSO standard with retention time of 4.67 
min.  
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Figure 7: (A) Unextracted analyte standard mixture for retention time verification. (B) Drug-free 
negative control. C) UHPLC-PDA chromatogram (240 nm, 4.5-9.0 min window) of 
chlorpromazine standard prepared at a concentration of 1000 ng/ml in BTE, and extracted by 
SPE. Extraneous peaks are labeled 1-3. UV absorbance spectrum associated with peak 1, 
retention time of 5.32 min, is compared to the spectrum of CPZSO standard, retention time of 
5.29.  
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Figure 8: (A) Unextracted analyte standard mixture for retention time verification. (B) Drug-free 
negative control. (C,D) UHPLC-q-TOF-MS total ion chromatograms of extracted promethazine 
and chlorpromazine standards at a concentration of 1000 ng/ml in BTE. Extraneous peaks are 
labeled 1-4. Below the TICs are the corresponding accurate mass spectra (MS) for each labeled 
peak in chromatograms C and D (MS-C, MS-D).  
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Figure 9:(A) Unextracted analyte standard mixture for retention time verification. (B) Drug-free 
negative control. (C,D) UHPLC-q-TOF-MS total ion chromatograms of extracted promethazine 
and chlorpromazine standards at a concentration of 1000 ng/ml in blood. Extraneous peaks are 
labeled 1-4. Below the TICs are the corresponding high-resolution mass spectra (MS) for each 
labeled peak in chromatograms C and D (MS-C, MS-D, respectively).  
MS-C	 MS-D	
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   As with bone tissue extract, extraneous peaks were observed in the TICs for extracted PMZ 
and CPZ standard samples when blood was utilized as the sample matrix (Fig. 9) that were not 
present in the analyte-free control. However, there was the presence of a new peak with retention 
time of 4.26 min and predominant ion with m/z 287.1553 in chromatogram C, and a new peak 
with retention time 4.94 min and predominant ion with m/z of 321.1142 in chromatogram D.  
Additionally, the peaks corresponding to PMZ and PMZ-N-oxide were not detected.  
2.3.3 Semi-Quantitative Comparison of Oxidation Products - Bone Tissue Extract 
vs Blood 
 
   Table 4 summarizes the relative extent oxidation of the parent compounds (PMZ and CPZ), 
indicated by increases in the peak area ratio (Asulfoxide/Aparent analyte). A baseline level of oxidation 
products were present in the analytical drug standards, however the extent of oxidation, indicated 
by increases in the peak area ratio (extra peak/parent analyte) increased drastically once the drug 
standards have been subjected to these sample preparation and extraction conditions. Data in 
Table 4 showed strong differences in the relative extent of oxidation between extracts from 
different sample matrices, with the greatest extent of oxidation observed when blood was used as 
the sample matrix. 
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Table 4: A semi-quantitative comparison of the relative extent of formation of PMZSO and 
CPZSO from the corresponding parent compound, based on the sample matrix: The mobile 
phase matrix an unextracted drug standard prepared in mobile phase A and analyzed. The peak 
area ratio is the ratio of the area of PMZSO or CPZSO relative to that of the parent analyte 
originally added (i.e., PMZ or CPZ). The peak area ratio is represented as a mean percentage 
(n=3). 
 
 Promethazine Chlorpromazine 
Matrix Mean Peak Area Ratio 
(APMZSO/APMZ 100%) 
Mean Peak Area Ratio 
(ACPZSO/ACPZ 100%) 
Mobile Phase A 3.9 3.9 
Bone Tissue Extract 70.8 71.3 
Blood 10,013 9,947 
 
2.3.4 Relative Extent of Phenothiazine Oxidation: Influence of Extraction 
Conditions 
 
   As described above, PMZ and CPZ oxidize during sample preparation producing the 
corresponding sulfoxides as well as other oxidation products. When the analyte standards were 
extracted from BTE individually using the sample preparation method of solid-phase extraction 
using an elution solution based on ethyl acetate, extraneous peaks were present in the total ion 
chromatogram (Figure 10).  The TIC for the extracted PMZ sample indicated the presence of 
compounds eluting at 4.71min (m/z 317.1356, Peak 1), 4.81 (m/z 301.1355, Peak 2), and 7.74 
(m/z 301.1426, Peak 3) (Figure 10, C). Peak 2 has been identified as PMZSO and Peak 3 has 
been identified as PMZNO and is the most abundant peak and oxidation product formed.  The 
TIC for the extracted CPZ sample indicated the presence of compounds eluting at 5.45min 
(335.1017, Peak 1), 5.82 (351.1020, Peak 2), and 6.18 (335.1054, Peak 3) and 8.23 (335.1054, 
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Peak 4). (Figure 10, D).  CPZSO has been identified as Peak 1 and Peak 4 is the most abundant 
oxidation product formed and is presumed to be chlorpromazine N-oxide.  
In an effort to minimize analyte oxidation, various sample preparation methods were evaluated. 
The next sample preparation method involved a simple switch to a different elution solvent while 
keeping all other variables constant. The elution solution used was 80:17:3 ,dichloromethane 
(DCM):iPrOH:NH4OH, as it is a commonly used solvent system for the elution of basic drugs. 
However, once again, precision and bias exceeded the 20% threshold. (Table 5). The 
chromatograms of extracts using a DCM-based elution solution also bore extraneous peaks, 
though, as shown in Figure 10 and Figure 11, it is apparent that the distribution and quantity of 
the extraneous peaks differs from experiments using an elution solution based on ethyl acetate.  
The TIC for the extracted PMZ sample indicated the presence of compounds eluting at 4.83 min 
(m/z 317.1665, Peak 1), 4.90 (m/z 301.1355, Peak 2), and 7.82 (m/z 301.1497, Peak 3) (Figure 
11, C). PMZSO (Peak 2) and PMZNO are present (Peak 3) in the sample, however the parent 
drug is the most abundant peak and the sulfoxide is the most abundant oxidation product. The 
TIC for the extracted CPZ sample indicated the presence of compounds eluting at 5.54min (m/z 
335.1166, Peak 1), 7.61 (m/z 285.1557, Peak 2). (Figure 11, D). The peak corresponding to CPZ 
is the most abundant peak, and CPZSO is the most abundant oxidation product (Peak 1). When 
the elution solvent was based on DCM, PMZ was formed as a degradation product (Peak 2) but 
this was not the case when ethyl acetate was utilized. 
The third sample preparation method involved FPTE instead of SPE. Substituting FPTE as the 
extraction method removed an elution step, which was presumed to be a factor contributing to 
the oxidation because of the strong organic nature of the elution solvent. The TIC for the 
extracted PMZ sample only contains one extra peak at a retention time of 4.89 (m/z 301.1264) 
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which corresponds to PMZSO (Figure 12, C).  The TIC for extracted CPZ contains three extra 
peaks, Peak 1(5.49min) is CPZSO, Peak 2 (7.50min) corresponds to the formation of PZ, and 
Peak 3 was a new extraneous peak at 7.73 min with an accurate mass of m/z 315.1455 (Figure 
12, D).  Although this method also caused oxidation products to form, the peak areas of the 
oxidation products have been reduced.  
The final sample preparation method that was developed was FPTE with no evaporation steps. 
As a result, it was a very simple preparation that included minimal steps that would influence or 
change the sample. Figure 13 demonstrates that this method did not cause any extra peaks to 
appear in the total ion chromatogram. Therefore, it is reasonable to conclude this method did not 
induce any measurable oxidation. 
 
Table 5: Summary of validation parameter results (LOD, LOQ, precision, linearity, bias). Solid-
phase extraction with dichloromethane elution solution was used as the sample preparation 
method and a UPLC-PDA as the analytical instrument. Data were collected over 5 different sets 
of extractions of analyte standard mixtures ranging from 25-10,000 ng/mL, where each standard 
concentration was analyzed in triplicate. 
Analyte Limit of 
Detection 
(LOD, 
ng/mL) 
Limit of 
Quantitation 
(LOQ, ng/mL) 
Precision 
(CV, %) 
(Acceptance 
Criteria: ≤ 20%) 
 [# failed] 
Linearity 
(Acceptance 
Criteria: 
R
2≥0.99) 
Bias (%) 
(Acceptance 
Criteria: ≤ 20%) 
[# failed] 
PMZ 10 25 0.9-18.7 [0/50] 0.9974 0.4-(197.6) [5/20] 
PMZSO 10 25 0.8-24.1 [3/50] 0.9917 0.3-(180.3) [7/20] 
DPMZ 10 25 0.7-21.9 [2/50] 0.9918 0.4-(55.6) [5/20] 
CPZ 10 25 0.9-38.3[1/50] 0.9960 -0.25-(61.8) [11/20] 
CPZSO 10 25 0.9-22.9[2/50] 0.9923 -1.9-(-306.9) [6/20] 
DCPZ 10 25 0.3-20.8 [1/50] 0.9938 -2.6-(-85.4) [12/20] 
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Figure 10: (A) Unextracted analyte standard mixture for retention time verification. (B) Drug-
free negative control. (C,D)  UHPLC-q-TOF-MS total ion chromatograms of extracted 
promethazine and chlorpromazine standards at a concentration of 1000 ng/ml in BTE using 
solid-phase extraction with ethyl acetate as the elution solution. . Extraneous peaks are labeled 1-
4. Below the TICs are the corresponding accurate mass spectra (MS) for each labeled peak in 
chromatograms C and D (MS-C, MS-D).  
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Figure 11: (A) Unextracted analyte standard mixture for retention time verification. (B) Drug-
free negative control. (C,D) UHPLC-q-TOF-MS total ion chromatograms of extracted 
promethazine and chlorpromazine standards at a concentration of 1000 ng/ml in BTE using 
solid-phase extraction with dichloromethane as the elution solution. Extraneous peaks are labeled 
1-3. Below the TICs are the corresponding accurate mass spectra (MS) for each labeled peak in 
chromatograms C and D (MS-C, MS-D). 
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Figure 12: (A) Unextracted analyte standard mixture for retention time verification. (B) Drug-
free negative control. (C,D).UHPLC-q-TOF-MS total ion chromatograms of extracted 
promethazine and chlorpromazine standards at a concentration of 1000 ng/ml in BTE using 
filtration as the extraction method. Extraneous peaks are labeled 1-3. Below the TICs are the 
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corresponding accurate mass spectra (MS) for each labeled peak in chromatograms C and D 
(MS-C, MS-D).  
 
 
Figure 13: (A) Unextracted analyte standard mixture for retention time verification. (B) Drug-
free negative control. (C,D,E) UHPLC-q-TOF-MS total ion chromatograms of extracted 
promethazine and chlorpromazine standards (n=3) at a concentration of 1000 ng/ml in BTE 
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using filtration without evaporation as the extraction method. Below the TICs are the 
corresponding accurate mass spectra (MS) for the peaks at 7.76 and 8.35, which correspond to 
promethazine and chlorpromazine, respectively.  
2.3.5 Semi-Quantitative Comparison of Oxidation Products - Comparing Different 
Extraction Conditions 
 
   Table 6 compares the relative formation of the oxidized species produced, based on the sample 
preparation method. As the method changes, the relative formation of the PMZSO changes as 
indicated by a decrease in the peak area ratio as we remove steps in the sample preparation 
method. FPTE converts less of the analyte to its corresponding oxidized form than solid-phase 
extraction and, if the evaporation step is removed, oxidation products are not formed. 
Furthermore, it is important to note that the deuterated internal standards also convert to their 
corresponding oxidized form to the same extent as the analytes in the unextracted standards 
(~4%).  
 
Table 6: A semi-quantitative comparison of the relative extent of formation of PMZSO and 
CPZSO from the corresponding parent compound, based on the sample preparation method. The 
unextracted drug standard is prepared in mobile phase A and analyzed. The peak area ratio is the 
ratio of the area of PMZSO or CPZSO relative to that of the parent analyte originally added (i.e., 
PMZ or CPZ). The peak area ratio is represented as a mean percentage (n=3). 
 Promethazine Chlorpromazine 
Method Mean Peak Area Ratio 
(APMZSO/APMZ 100%) 
Mean Peak Area Ratio 
(ACPZSO/ACPZ 100%) 
SPE EA Elution Solution 67.0 89.2 
SPE DCM Elution Solution 38.9 48.9 
Filtration with Evaporation 16.3 13.8 
Filtration without Evaporation 3.6 3.0 
Unextracted Standards 3.9 3.6 
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2.3.6 Method Validation Results 
 
   Using FTPE without evaporation, the validation process was undertaken, with concentration 
dependence, LOD, LOQ, precision, accuracy, recovery and matrix effects assessed according to 
SWGTOX guidelines (68). All analytes were fit with quadratic regression lines and 
concentration dependence was assessed over the range 10 to 2000 ng/mL. Correlation 
coefficients of r
2
>0.99 were observed over 5 different days. The LOD and LOQ were determined 
to be 10 ng/mL for all analytes. Summarized in Table 7 are the precision and accuracy data 
which proved to be acceptable ranging from 0.04%-14%, and 0.09% - 20%, respectively. 
Recovery ranged from 90%-110% and the matrix effects calculations revealed that the average 
suppression or enhancement did not exceed 25% for all analytes. Analyte stability while resident 
on the autosampler tray in extracted samples revealed there was no loss in analyte response in 
excess of 20% of the initial response ratio at t=0 hr for all analytes except for the PMZ-D3 
internal standard. At the 24 hr time interval, PMZ-D3 demonstrated loss in response exceeding 
the 20% threshold. However, this instability did not affect the precision or accuracy of the 
standard curves, this could be because the time required to analyze all curve samples on the 
instrument doesn’t commonly exceed 15 hr.  
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Table 7: Summary of validation parameter results (LOD, LOQ, precision, linearity, bias). 
Filtration without evaporation was used as the sample preparation method and a UPLC-QTOF-
MS as the analytical instrument.  Data were collected over 4 different sets of extractions of 
analyte standard mixtures ranging from 10-2,000 ng/mL, where each standard concentration was 
analyzed in triplicate. 
Analyte Limit of 
Detection 
(LOD, 
ng/mL) 
Limit of 
Quantitation 
(LOQ, ng/mL) 
Precision 
(CV, %) 
(Acceptance 
Criteria: ≤ 20%) 
 [# failed] 
Linearity 
(Acceptance 
Criteria: 
R
2≥0.99) 
Bias (%) 
(Acceptance 
Criteria: ≤ 20%) 
[# failed] 
PMZ 10 10 0.04-8.2[0/34] 0.998 1.4-(-17.4) [0/10] 
PMZSO 10 10 0.37-13.9[0/34] 0.998 -1.4-(18.5) [0/10] 
DPMZ 10 10 0.8-10.8 [0/34] 0.998 -1.1-(8.4) [0/10] 
CPZ 10 10 0.9-13.79[0/34] 0.999 0.55-(19.9) [0/10] 
CPZSO 10 10 0.7-11.9[0/34] 0.998 0.66-(13.6) [0/10] 
DCPZ 10 10 0.2-12.7 [0/34] 0.998 0.09-(18.1) [0/10] 
 
2.4 Discussion 
 
    The initial purpose of this research was to develop and validate a semi-quantitative method to 
evaluate the relative distribution of selected phenothiazine drugs (PMZ and CPZ), and their N-
desmethyl and sulfoxide metabolites in skeletal remains. The method was intended for 
application to studies examining different PMZ and CPZ exposure patterns to understand the 
significance of drug and metabolite levels in toxicological analysis of bone, and to assess 
whether their small differences in chemical structure were associated with significant differences 
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in the patterns of drug and metabolite distribution. During the characterization of analytical 
figures of merit, precision and bias were not consistently meeting the required criteria (≤ 20%). 
UPLC-PDA chromatograms from extracted standards showed extraneous peaks and further 
experiments revealed that the analytes were degrading during sample preparation.  Consequently, 
the main objective of the work shifted to the characterization of analyte degradation. 
   As demonstrated by the results, the parent drugs (PMZ, CPZ) underwent oxidation during 
sample preparation and extraction. Through analysis of analytical reference standards, we 
confirmed that PMZ was oxidized to its corresponding sulfoxide and N-oxide while CPZ was 
oxidized to its corresponding sulfoxide. Thus, some of the oxidation products included naturally 
occurring metabolites of the drugs.  In addition to the identified oxidation products, other 
products were formed for which the putative identity include the sulfone, sulfoxide-N-oxide, 
chlorpromazine N-oxide or hydroxylated form of the parent drug. The oxidation was also 
observed in analysis of whole blood, and to a greater extent, which indicates the phenomenon 
does not occur only in bone tissue extract.  Furthermore, the autosampler stability results provide 
strong evidence that the oxidation took place during the extraction , before the sample was 
placed on the instrument, and did not occur over time as the samples remained on the 
autosampler tray.  
2.4.1 Sample Preparation of Basic Drugs 
 
   The complexity of biological samples has led to the development of numerous sample 
preparation techniques, and the selection of a suitable technique is based on chemical properties 
of the drug, the biological matrix and the limitations of the analytical instrumentation. Solid 
phase extraction (SPE) has become a common extraction technique used in forensic toxicology 
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because of the advantages with respect to amenability to automation, high selectivity, and 
cleanliness of extracts. Methods for SPE of basic drugs has been described (84,88-93) which 
employ solvents such as those utilized in this work (i.e., phosphate buffer, water, methanol, 
acetic acid, ethyl acetate, ammonium hydroxide and isopropanol).  Work in our laboratory has 
successfully demonstrated the use of SPE for analysis of various basic drugs, including 
amitriptyline (94), dextromethorphan (86), meperidine (95), ketamine (96) and their metabolites 
in skeletal tissues using standard protocols. Research in our laboratory continues with the aim of 
assessment of the distribution patterns of drugs of forensic relevance with various 
physicochemical characteristics (e.g, acid-base character, volume of distribution, half-life, etc). 
The phenothiazines investigated here are relevant to post-mortem casework (97-105), and thus 
presented an interesting opportunity to compare skeletal drug and metabolite distribution patterns 
between structural analogues. 
2.4.2 Oxidation of Phenothiazines 
  The susceptibility of phenothiazines to oxidation has been reported (106-31), although the 
majority of such work was done between 1950-1990. The most commonly reported oxidation 
occurs at the sulfide linkage which first forms an unstable radical cation that leads to the 
generation of the sulfoxide. After the sulfoxide is formed, subsequent oxidation can occur which 
results in the formation of the sulfone (113-115). Various factors have been noted to influence 
the oxidation reaction including acidity, concentration of oxidizing agents, time, temperature and 
the side-chain of the molecule (110-112). Much of the research describing phenothiazine 
oxidation has focused on the generation of oxidation products by chemical, electrochemical, 
enzymatic and catalytic means (112,114,116-118). The oxidation of phenothiazines remains a 
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complex subject, largely depending on the experimental conditions and debate about the 
mechanisms and products formed continues.  
   To the authors’ knowledge, no published articles in the analytical toxicology literature have 
reported oxidation of the phenothiazine drugs during the process of preparation of biological 
samples for analysis. It is possible that the formation of oxidation products may go unnoticed, 
depending on the sample preparation methods and analytical instrumentation employed. For 
example, with the use of targeted methods such as GC/MS in SIM mode, or LC/MS/MS in MRM 
mode, ions corresponding to the oxidation products may not arise in the appropriate time 
window, or they may be completely excluded from the list of ions or transitions used. For those 
methods that monitor sulfoxide metabolites, the presence of sulfoxide in any given calibrant or 
sample chromatogram is expected. Provided that the oxidation reaction occurs in a reproducible 
and concentration dependent manner, acceptable standard curves could be generated in a given 
assay. 
   The results of this work suggest that the extent of oxidation is highly reproducible under these 
sample preparation conditions, as the measured CV values in replicate analyses of all analytes 
were less than 20% in over 90% of extractions done (Table 3). If the extent of oxidation was not 
reproducible, a much wider variability in measured precision and bias values would be expected. 
This reproducibility represents another reason that analyte oxidation during sample preparation 
might go unnoticed. 
2.4.3 Effect of Matrix on Phenothiazine Oxidation 
 
   The data presented here suggests that the extent of oxidation and the products formed may vary 
between sample matrices, as shown in comparing data from samples prepared in bone tissue 
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extract (Fig. 8) to those prepared in blood (Fig. 9). This is consistent with studies reporting the 
oxidation of sulfide functionalities due to various reactive molecules present in blood (50,51). 
The authors noticed that CPZ is converted to CPZSO in whole blood, but a large conversion is 
due to the set-up of the analytical procedure (50,51). Given the wide variation in the nature of 
sample matrices in post-mortem toxicology, it is likely that the extent of phenothiazine oxidation 
could differ from sample to sample. Thus, even though the vast majority of bias estimations from 
the various extractions performed were within acceptable limits, this was likely because the same 
blank matrix was used in preparation of calibrants and the positive control samples used in 
measurement of accuracy, resulting in a similar extent of oxidation between them. In casework, 
the matrix used for preparation of standard curves necessarily differs from that of a given 
sample, and the extent of oxidation may be expected to also differ. Hence, measured 
phenothiazine and metabolite concentrations may be inaccurate, interfering with toxicological 
interpretation of the results. 
2.4.4 Effect of Extraction Conditions on Phenothiazine Oxidation 
 
    The original purpose of this study was to develop and validate a method for the analysis of 
selected phenothiazine drugs and their respective desmethyl and sulfoxide metabolites in 
decomposed skeletal remains of rats. Initial attempts to validate the method, according to 
SWGTOX requirements, utilizing microplate solid-phase extraction using an elution solution 
based on ethyl acetate, and analysis by UPLC-PDA, were unsuccessful. Results showed that 
analytes were degrading by oxidation during sample preparation and some of the oxidation 
products included naturally occurring metabolites of the drugs being assayed. In some cases, the 
oxidation resulted in unacceptable bias and precision. Therefore, the focus of the work shifted 
towards identification of the source of the oxidation and redesign of the analytical method such 
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that the oxidation was minimized or eliminated.  The first area that was investigated was the 
elution step in the SPE process. Experiments where PMZ and CPZ standards were dissolved 
directly in the ethyl acetate-based elution solvent and then evaporated to dryness (i.e., no 
extraction step from biological matrix) showed extensive oxidation. We theorized that the drugs 
were degrading due to elution solvent instability and as a result switched from dichloromethane 
to ethyl acetate. However, as Figures 10,11 and Table 6 depict ethyl acetate caused a greater 
number of oxidation products to form and the relative amount of oxidation product formed was 
higher.  Next, numerous experiments were conducted such as reducing the temperature of the 
Centrivap from 70
0
C to 40
0
C, eliminating exposure to light, and evaporation under argon gas 
instead of vacuum centrifugation. None of these alterations eliminated oxidation. The subsequent 
sample preparation method that was employed removed the elution step completely by utilizing 
FPTE in place of SPE. The results were promising (Fig. 12 and Table 6), with reduced oxidation 
of PMZ and CPZ.  
   Based on the minimal presence of oxidation products in neat standards, the evaporation step of 
the FPTE process was removed.  By removing the evaporation step, no additional oxidation was 
induced, and the amount of oxidation product formed was the same as in the unextracted neat 
standard (Fig. 13, Table 6). Given that this new sample preparation method was able to eliminate 
the degradation of the phenothiazines, we were able to successfully validate it for the analysis of 
PMZ, CPZ and their corresponding metabolites. In comparing the results of the four sample 
preparation methods we are able to conclude that sample preparation method highly influenced 
the extent of oxidation, specifically the type and relative formation of the oxidized species 
produced.  
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2.4.6 Conclusions 
 
   We have demonstrated that degradation of selected phenothiazines occurred by oxidation 
during sample preparation. The oxidation products observed included common metabolites of the 
parent drug and may confound toxicological interpretation. The incidence of oxidation may not 
be detected by certain analytical configurations. These results are of particular importance for 
laboratories employing tandem MS methods for analysis of phenothiazines based on MRM. 
Also, the variability in the extent of oxidation between different samples and calibrators may 
yield erroneous results. Our work also established the influence of changing the sample 
preparation method on the extent of oxidation. A new simple extraction method was developed 
and validated for the analysis of phenothiazines in skeletal tissues that did not measurably 
generate any oxidation products. 
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Chapter 3 
 
3.1 Conclusion 
 
In the present study, it was demonstrated that promethazine and chlorpromazine have stability 
issues due to their susceptibility to oxidation at the sulfur and nitrogen atoms. While using a 
method that was causing PMZ and CPZ to be converted to their corresponding oxidation 
products, respectable coefficient of variation values were achieved. Thus, there may be nothing 
to alert an unsuspecting analyst when data are erroneous during analysis of patient samples with 
PMZ or CPZ. Furthermore, the extent of oxidation and the products formed may vary between 
sample matrices and as a result will differ from sample to sample. The results of this work also 
established that the phenomenon of oxidation will vary between different analytical methods and 
this is a concern because not all laboratories will use the same method causing them to produce 
dissimilar results. In conclusion, the analysis of phenothiazines may lead to overestimation or 
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underestimation and lead to false toxicological interpretations. It is important to create an 
experimental design that includes various stability experiments and it is necessary to develop an 
analytical method where degradation does not occur.  
3.2 Future Work 
 
The data generated in this study will support future work applying this method to study the 
disposition of promethazine and chlorpromazine in bone and the effects of different drug 
exposure patterns such as acute vs. repeated and the delay between exposure and death. Other 
potential research would include examining the stability of other phenothiazines to determine 
their predisposition to oxidation. Lastly, applying the validated method to multiple 
phenothiazines to ensure its applicability and reproducibility.  
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